Liposomal Bupivacaine (Exparel) for Inguinal Hernia

Karl LeBlanc, Baton Rouge, LA
Inguinal Hernia+1 More ConditionsLiposomal Bupivacaine - Drug
All Sexes

Study Summary

This trial found that Exparel provides superior postoperative pain control compared to bupivacaine alone in minimally invasive ventral and inguinal hernia repair patients.

Eligible Conditions
  • Inguinal Hernia
  • Ventral Hernia

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase < 1

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: After 1 week post-operation

After 1 week post-operation
Opioids Used Post-Operatively related to Hernia Size and Surgical Time
For 1 Week post-operation
Opioids Used Post-Operatively compared in anesthesia arms
For 1 week post-operation
Subjective Pain Scores using Visual Analog Scale (VAS)

Trial Safety

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.

Trial Design

2 Treatment Groups

Liposomal Bupivacaine (Exparel)
1 of 2
Bupivacaine (Marcaine)
1 of 2

Active Control

200 Total Participants · 2 Treatment Groups

Primary Treatment: Liposomal Bupivacaine (Exparel) · No Placebo Group · Phase < 1

Liposomal Bupivacaine (Exparel)
ActiveComparator Group · 1 Intervention: Liposomal Bupivacaine · Intervention Types: Drug
Bupivacaine (Marcaine)
ActiveComparator Group · 1 Intervention: Bupivacaine · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: after 1 week post-operation

Who is running the clinical trial?

Leslie SonLead Sponsor
Our Lady of the Lake Regional Medical CenterOTHER
5 Previous Clinical Trials
269 Total Patients Enrolled
Leslie Son, PhDStudy DirectorOur Lady of the Lake Regional Medical Center

Eligibility Criteria

Age 18+ · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Who else is applying?

What state do they live in?
How old are they?
18 - 65100.0%
What site did they apply to?
Karl LeBlanc100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%

How responsive is this trial?

Typically responds via

Frequently Asked Questions

How many participants are being invited to participate in this scientific investigation?

"Affirmative, the data hosted on suggests that this trial is currently recruiting patients for participation. This medical experiment was initially posted on March 1st 2022 and has been modified as recently as April 19th 2022. Approximately 200 individuals from a single location are needed to take part in the study." - Anonymous Online Contributor

Unverified Answer

What other research initiatives have been implemented to evaluate Liposomal Bupivacaine (Exparel)?

"Currently, the clinical trial landscape for Liposomal Bupivacaine (Exparel) includes 110 active studies with 18 trials in Phase 3. Philadelphia, Pennsylvania hosts many of these experiments but there are also 147 other locations where such research is taking place." - Anonymous Online Contributor

Unverified Answer

Are participants sought for this ongoing trial?

"Indeed, the information available on signifies that this medical experiment is soliciting enrolment. It was first published in March 1st 2022 and underwent its last revision on April 19th of the same year. This study seeks to enroll up to 200 patients from a single site." - Anonymous Online Contributor

Unverified Answer

In what clinical scenarios is Liposomal Bupivacaine (Exparel) regularly prescribed?

"Liposomal Bupivacaine (Exparel) is frequently prescribed for permphigus patients. It can also provide relief to individuals dealing with acute nonspecific tenosynovitis, general anesthesia, and lupus erythematosus cell related issues." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.